论文部分内容阅读
本研究目的是观察CD19和CD20在急性白血病(AL)细胞中的表达与分布,为急性B系白血病靶向分子 的选择提供合理依据。采用27个荧光直标单克隆抗体及CD45/SSC双参数设门多色流式细胞术对321例AL细胞 进行免疫诊断和分型,并对CD19和CD20在各种类型AL细胞中的表达情况进行分析。结果表明,在116例B系 ALL病例中,CD19持续稳定表达,其阳性率(115/116,99.1%)明显高于CD20(33/116,28.4%,P=0.001);在 17例含B系成分的混合型白血病(acutemixedlineageleukemia,AMLL)细胞中,前者的阳性率也明显高于CD20(P <0.01),而在29例T细胞系ALL和7例T/MyHAL细胞中,两者均无表达;在152例急性髓系白血病(AML)细胞 中,CD19和CD20阳性率均很低,分别为7.2%和2.0%;CD19和CD20在B ALL及B/MyAMLL组中的荧光强度差 别有显著性(t=20.68,P<0.001);CD19和CD20的特异性分别为92.3%(132/143)和92.7%(38/41),敏感 性分别为99.2%(132/133)和28.6%(38/133),前者敏感性明显高于后者(χ2=144.018,P=0.001)。结论: CD19在B细胞系细胞的各分化阶段上持续稳定表达,反应谱比CD20宽,特异性及敏感性均高,尤其是其敏感性显 著高于后者。这提示CD19抗原分子可能成为治疗B系ALL的最佳靶点。
The purpose of this study was to observe the expression and distribution of CD19 and CD20 in acute leukemia (AL) cells and to provide a reasonable basis for the selection of target molecules for acute leukemia. Twenty-seven cases of AL were immunologically diagnosed and classified using 27 fluorescent direct monoclonal antibodies and CD45 / SSC double-parameter multiplex multicolor flow cytometry, and the expression of CD19 and CD20 in various types of AL cells Analyze. The results showed that CD19 was stably expressed in 116 B-lineage ALL cases, and the positive rate of CD19 was significantly higher than that of CD20 (33 / 116,28.4%, P = 0.001) The positive rate of the former was also significantly higher than that of CD20 in acutemixed lineageleukemia (AMLL) cells, while in 29 T cell line ALL and 7 T / MyHAL cells, none of them . The positive rates of CD19 and CD20 in 152 acute myeloid leukemia (AML) cells were very low (7.2% and 2.0% respectively). There was a significant difference in the fluorescence intensity between CD19 and CD20 in B ALL and B / MyAMLL group The specificity of CD19 and CD20 were 92.3% (132/143) and 92.7% (38/41), respectively, with a sensitivity of 99.2% (132/133) and 28.6% (t = 20.68, 38/133), the former was significantly higher than the latter (χ2 = 144.018, P = 0.001). CONCLUSION: CD19 is stably expressed in all the differentiation stages of B cell line. The response spectrum is broader, more specific and more sensitive than CD20, especially its sensitivity is higher than that of CD20. This suggests that CD19 antigen molecules may become the best target for the treatment of B lineage ALL.